Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study

Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study

Abstract Background To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate. Methods In this double-blind, placebo-controlled phase 3 trial, biolog...

Full description

Bibliographic Details
Main Authors: Xiaofeng Zeng, Ju Liu, Xiumei Liu, Lijun Wu, Yi Liu, Xiangping Liao, Huaxiang Liu, Jiankang Hu, Xin Lu, Linjie Chen, Jian Xu, Zhenyu Jiang, Fu-ai Lu, Huaxiang Wu, Ying Li, Qingyu Wang, Jun Zhu, the HLX01-RA03 Investigators
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Rituximab
Methotrexate
Phase 3
Biologic disease-modifying anti-rheumatic drug
Online Access:https://doi.org/10.1186/s13075-022-02821-x

Internet

https://doi.org/10.1186/s13075-022-02821-x

Similar Items